Please login to the form below

Not currently logged in
Email:
Password:

ceralifimod

This page shows the latest ceralifimod news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA drops Ono-partnered multiple sclerosis drug

Merck KGaA drops Ono-partnered multiple sclerosis drug

The German pharma company said in a statement that ceralifimod (ONO-4641) "does not meet Merck's threshold for continued investment". . ... Ceralifimod is a sphingosine-1-phosphate (S1P) receptor-1 and -5 agonist and was licensed by Merck in 2011 for

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics